Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch

Alternative delivery systems such as the high-density microarray patch (HD-MAP) are being widely explored due to the variety of benefits they offer over traditional vaccine delivery methods. As vaccines are dry coated onto the HD-MAP, there is a need to ensure the stability of the vaccine in a solid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jovin J. Y. Choo, Christopher L. D. McMillan, Germain J. P. Fernando, Roy A. Hall, Paul R. Young, Jody Hobson-Peters, David A. Muller
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	dengue high-density microarray patch microneedles dengue vaccine chimeric virus formulation Medicine R
Acceso en línea:	https://doaj.org/article/c3781db295914ec3b1fdb0bb6b7d13c9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c3781db295914ec3b1fdb0bb6b7d13c9
record_format	dspace
spelling	oai:doaj.org-article:c3781db295914ec3b1fdb0bb6b7d13c92021-11-25T19:11:07ZDeveloping a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch10.3390/vaccines91113012076-393Xhttps://doaj.org/article/c3781db295914ec3b1fdb0bb6b7d13c92021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1301https://doaj.org/toc/2076-393XAlternative delivery systems such as the high-density microarray patch (HD-MAP) are being widely explored due to the variety of benefits they offer over traditional vaccine delivery methods. As vaccines are dry coated onto the HD-MAP, there is a need to ensure the stability of the vaccine in a solid state upon dry down. Other challenges faced are the structural stability during storage as a dried vaccine and during reconstitution upon application into the skin. Using a novel live chimeric virus vaccine candidate, BinJ/DENV2-prME, we explored a panel of pharmaceutical excipients to mitigate vaccine loss during the drying and storage process. This screening identified human serum albumin (HSA) as the lead stabilizing excipient. When bDENV2-coated HD-MAPs were stored at 4 °C for a month, we found complete retention of vaccine potency as assessed by the generation of potent virus-neutralizing antibody responses in mice. We also demonstrated that HD-MAP wear time did not influence vaccine deposition into the skin or the corresponding immunological outcomes. The final candidate formulation with HSA maintained ~100% percentage recovery after 6 months of storage at 4 °C.Jovin J. Y. ChooChristopher L. D. McMillanGermain J. P. FernandoRoy A. HallPaul R. YoungJody Hobson-PetersDavid A. MullerMDPI AGarticledenguehigh-density microarray patchmicroneedlesdengue vaccinechimeric virusformulationMedicineRENVaccines, Vol 9, Iss 1301, p 1301 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	dengue high-density microarray patch microneedles dengue vaccine chimeric virus formulation Medicine R
spellingShingle	dengue high-density microarray patch microneedles dengue vaccine chimeric virus formulation Medicine R Jovin J. Y. Choo Christopher L. D. McMillan Germain J. P. Fernando Roy A. Hall Paul R. Young Jody Hobson-Peters David A. Muller Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch
description	Alternative delivery systems such as the high-density microarray patch (HD-MAP) are being widely explored due to the variety of benefits they offer over traditional vaccine delivery methods. As vaccines are dry coated onto the HD-MAP, there is a need to ensure the stability of the vaccine in a solid state upon dry down. Other challenges faced are the structural stability during storage as a dried vaccine and during reconstitution upon application into the skin. Using a novel live chimeric virus vaccine candidate, BinJ/DENV2-prME, we explored a panel of pharmaceutical excipients to mitigate vaccine loss during the drying and storage process. This screening identified human serum albumin (HSA) as the lead stabilizing excipient. When bDENV2-coated HD-MAPs were stored at 4 °C for a month, we found complete retention of vaccine potency as assessed by the generation of potent virus-neutralizing antibody responses in mice. We also demonstrated that HD-MAP wear time did not influence vaccine deposition into the skin or the corresponding immunological outcomes. The final candidate formulation with HSA maintained ~100% percentage recovery after 6 months of storage at 4 °C.
format	article
author	Jovin J. Y. Choo Christopher L. D. McMillan Germain J. P. Fernando Roy A. Hall Paul R. Young Jody Hobson-Peters David A. Muller
author_facet	Jovin J. Y. Choo Christopher L. D. McMillan Germain J. P. Fernando Roy A. Hall Paul R. Young Jody Hobson-Peters David A. Muller
author_sort	Jovin J. Y. Choo
title	Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch
title_short	Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch
title_full	Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch
title_fullStr	Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch
title_full_unstemmed	Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch
title_sort	developing a stabilizing formulation of a live chimeric dengue virus vaccine dry coated on a high-density microarray patch
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c3781db295914ec3b1fdb0bb6b7d13c9
work_keys_str_mv	AT jovinjychoo developingastabilizingformulationofalivechimericdenguevirusvaccinedrycoatedonahighdensitymicroarraypatch AT christopherldmcmillan developingastabilizingformulationofalivechimericdenguevirusvaccinedrycoatedonahighdensitymicroarraypatch AT germainjpfernando developingastabilizingformulationofalivechimericdenguevirusvaccinedrycoatedonahighdensitymicroarraypatch AT royahall developingastabilizingformulationofalivechimericdenguevirusvaccinedrycoatedonahighdensitymicroarraypatch AT paulryoung developingastabilizingformulationofalivechimericdenguevirusvaccinedrycoatedonahighdensitymicroarraypatch AT jodyhobsonpeters developingastabilizingformulationofalivechimericdenguevirusvaccinedrycoatedonahighdensitymicroarraypatch AT davidamuller developingastabilizingformulationofalivechimericdenguevirusvaccinedrycoatedonahighdensitymicroarraypatch
_version_	1718410241374158848

Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch

Ejemplares similares